Back to Studies Overview

The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be

Study Name on 
ClinicalTrials.gov
Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients
Study Drug QBW251
Type of Study Drug CFTR Modulation
Study Title A randomized, double blind placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamics of single and multiple ascending doses of QBW251 in healthy subjects and multiple doses in cystic fibrosis patients
Study Phase 2
Study Sponsor Novartis
Link onclincaltrials.gov

http://clinicaltrials.gov/ct2/show/study/NCT02190604

Participating ECFS-CTN sites

France: Lyon, Montpellier, West-Paris(Cochin)
Germany : Berlin, Cologne
Italy: Firenze, Genua, Milan, Rome, Verona
The Netherlands: Utrecht
UK: Belfast, London

Age 18 Years to 55 Years


Back to Studies Overview